These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 11162510

  • 21. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA, Vellon L, Lupu R.
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [Abstract] [Full Text] [Related]

  • 22. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
    Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES.
    Clin Cancer Res; 2002 Jun; 8(6):1720-30. PubMed ID: 12060609
    [Abstract] [Full Text] [Related]

  • 23. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells.
    Li X, Stuckert P, Bosch I, Marks JD, Marasco WA.
    Cancer Gene Ther; 2001 Aug; 8(8):555-65. PubMed ID: 11571533
    [Abstract] [Full Text] [Related]

  • 24. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
    Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM.
    Cancer Res; 2005 Jan 15; 65(2):473-82. PubMed ID: 15695389
    [Abstract] [Full Text] [Related]

  • 25. A new human antitumor immunoreagent specific for ErbB2.
    De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D'Alessio G.
    Clin Cancer Res; 2002 Jun 15; 8(6):1710-9. PubMed ID: 12060608
    [Abstract] [Full Text] [Related]

  • 26. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells.
    Neve RM, Sutterlüty H, Pullen N, Lane HA, Daly JM, Krek W, Hynes NE.
    Oncogene; 2000 Mar 23; 19(13):1647-56. PubMed ID: 10763821
    [Abstract] [Full Text] [Related]

  • 27. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
    Camirand A, Lu Y, Pollak M.
    Med Sci Monit; 2002 Dec 23; 8(12):BR521-6. PubMed ID: 12503030
    [Abstract] [Full Text] [Related]

  • 28. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
    Tan M, Lan KH, Yao J, Lu CH, Sun M, Neal CL, Lu J, Yu D.
    Cancer Res; 2006 Apr 01; 66(7):3764-72. PubMed ID: 16585203
    [Abstract] [Full Text] [Related]

  • 29. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M, Weth R, Wels WS.
    J Mol Biol; 2005 Mar 11; 346(5):1299-311. PubMed ID: 15713482
    [Abstract] [Full Text] [Related]

  • 30. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
    Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL.
    Cancer Res; 2001 Sep 01; 61(17):6583-91. PubMed ID: 11522658
    [Abstract] [Full Text] [Related]

  • 31. Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells.
    Jannot CB, Beerli RR, Mason S, Gullick WJ, Hynes NE.
    Oncogene; 1996 Jul 18; 13(2):275-82. PubMed ID: 8710366
    [Abstract] [Full Text] [Related]

  • 32. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ.
    Oncogene; 1998 Oct 29; 17(17):2235-49. PubMed ID: 9811454
    [Abstract] [Full Text] [Related]

  • 33. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep 29; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

  • 34. Intracellular single-chain antibody directed against erbB2 down-regulates cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing cancer cell lines.
    Deshane J, Loechel F, Conry RM, Siegal GP, King CR, Curiel DT.
    Gene Ther; 1994 Sep 29; 1(5):332-7. PubMed ID: 7584099
    [Abstract] [Full Text] [Related]

  • 35. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
    Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL.
    Cancer Res; 2002 Jul 15; 62(14):4132-41. PubMed ID: 12124352
    [Abstract] [Full Text] [Related]

  • 36. Expression of ErbB2 enhances radiation-induced NF-kappaB activation.
    Guo G, Wang T, Gao Q, Tamae D, Wong P, Chen T, Chen WC, Shively JE, Wong JY, Li JJ.
    Oncogene; 2004 Jan 15; 23(2):535-45. PubMed ID: 14724581
    [Abstract] [Full Text] [Related]

  • 37. Novel method for differentiation between Trastuzumab and host adaptive response.
    Denisova G, Jenkins K, Evelegh C, Bramson J.
    Mol Immunol; 2011 Sep 15; 48(15-16):1882-5. PubMed ID: 21645926
    [Abstract] [Full Text] [Related]

  • 38. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
    Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J.
    Cancer Res; 2001 Jun 15; 61(12):4744-9. PubMed ID: 11406546
    [Abstract] [Full Text] [Related]

  • 39. Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv.
    Arafat WO, Gómez-Navarro J, Buchsbaum DJ, Xiang J, Wang M, Casado E, Barker SD, Mahasreshti PJ, Haisma HJ, Barnes MN, Siegal GP, Alvarez RD, Hemminki A, Nettelbeck DM, Curiel DT.
    Gene Ther; 2002 Feb 15; 9(4):256-62. PubMed ID: 11896464
    [Abstract] [Full Text] [Related]

  • 40. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
    Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL.
    Oncogene; 2005 Sep 15; 24(41):6213-21. PubMed ID: 16091755
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.